Change in NLR and Survival Among Advanced Lung Cancer Patients Receiving ICIs With Immunomodulator

Completed

• Conditions: Advanced Lung Cancer

• Registration Number: NCT04352335
• Lead Sponsor: Chung Shan Medical University

Brief Summary

The main objective of this study is to evaluate the change of neutrophil to lymphocyte ratio (NLR) after 6-week treatment of immune checkpoint inhibitors (ICIs) with or without immunomodulatory drugs and recognize the effect of post-treatment NLR and overall survival in advanced lung cancer patients by retrospective review.

Detailed Description

In recent years, the therapeutic strategies for lung cancer have been enriched with small molecular targeted therapy and immunotherapy. In this retrospective study, we will observe the change in NLR and explore its possible association with survival among advanced lung cancer patients receiving Immune checkpoint inhibitors (ICIs) with and without such immuno-modulator, Astragalus Polysaccharide Injection. It can be used to understand the relationship between NLR values and the survival rate of lung cancer patients after ICIs treatment. Physicians can refer to this result to give patients the suitable treatment recommendations.

Study Timeline

• Study Start: 2020-04-14
• Study First Submitted: 2020-04-16
• Study First Submitted QC: 2020-04-17
• Study First Posted: 2020-04-20
• Status Verified: 2020-06
• Last Update Submitted: 2020-06-30
• Primary Completion: 2020-07-01
• Study Completion: 2020-07-01
• Last Update Posted: 2020-07-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 53

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Neutrophil to lymphocyte ratio (NLR)	Baseline, 4~8 week

Secondary Outcome Measures

Name	Time	Method
Overall Survival (OS)	4 years

Trial Locations

Locations (1)

Chung Shan Medical University Hospital; 🇨🇳 Taichung, Taiwan